These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 37379264)
21. Assessing the Effectiveness of Treatment Sequences for Older Patients With High-risk Follicular Lymphoma With a Multistate Model. Çağlayan Ç; Terawaki H; Ayer T; Goldstein JS; Rai A; Chen Q; Flowers C Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):300-309.e5. PubMed ID: 30686772 [TBL] [Abstract][Full Text] [Related]
22. EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment. Martínez-Laperche C; Sanz-Villanueva L; Díaz Crespo FJ; Muñiz P; Martín Rojas R; Carbonell D; Chicano M; Suárez-González J; Menárguez J; Kwon M; Diez Martín JL; Buño I; Bastos Oreiro M BMC Cancer; 2022 Sep; 22(1):982. PubMed ID: 36104682 [TBL] [Abstract][Full Text] [Related]
23. Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. Luminari S; Ferrari A; Manni M; Dondi A; Chiarenza A; Merli F; Rusconi C; Tarantino V; Tucci A; Vitolo U; Kovalchuk S; Angelucci E; Pulsoni A; Arcaini L; Angrilli F; Gaidano G; Stelitano C; Bertoldero G; Cascavilla N; Salvi F; Ferreri AJM; Vallisa D; Marcheselli L; Federico M J Clin Oncol; 2018 Mar; 36(7):689-696. PubMed ID: 29095677 [TBL] [Abstract][Full Text] [Related]
24. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ; Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632 [TBL] [Abstract][Full Text] [Related]
25. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W; Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325 [TBL] [Abstract][Full Text] [Related]
26. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191 [TBL] [Abstract][Full Text] [Related]
27. R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. Friedberg JW; Unger JM; Burack WR; Gopal AK; Raju RN; Nademanee AP; Kaminski MS; Li H; Press OW; Miller TP; Fisher RI Br J Haematol; 2014 Aug; 166(3):382-9. PubMed ID: 24749780 [TBL] [Abstract][Full Text] [Related]
28. Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi. Nizzoli ME; Manni M; Ghiggi C; Pulsoni A; Musuraca G; Merli M; Califano C; Bari A; Massaia M; Conconi A; Musto P; Mannina D; Perrone T; Re F; Galimberti S; Gini G; Capponi M; Vitolo U; Usai SV; Stefani PM; Ballerini F; Liberati AM; Pennese E; Pastore D; Skrypets T; Catellani H; Marcheselli L; Federico M; Luminari S Hematol Oncol; 2023 Oct; 41(4):655-662. PubMed ID: 37246287 [TBL] [Abstract][Full Text] [Related]
29. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
30. Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma. Derenzini E; Stefoni V; Maglie R; Casadei B; Pellegrini C; Broccoli A; Stefani G; Fanti S; Motta MR; Narducci R; Argnani L; Zinzani PL Biol Blood Marrow Transplant; 2013 Dec; 19(12):1695-701. PubMed ID: 24055654 [TBL] [Abstract][Full Text] [Related]
31. Signal transducers and activators of transcription 5a-dependent cross-talk between follicular lymphoma cells and tumor microenvironment characterizes a group of patients with improved outcome after R-CHOP. Taskinen M; Valo E; Karjalainen-Lindsberg ML; Hautaniemi S; Meri S; Leppä S Clin Cancer Res; 2010 May; 16(9):2615-23. PubMed ID: 20388848 [TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain. Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915 [TBL] [Abstract][Full Text] [Related]
33. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. Tilly H; Morschhauser F; Casasnovas O; Molina TJ; Feugier P; Gouill SL; Haioun C; Tournilhac O; Bouabdallah R; Gabarre J; Lamy T; Cabeçadas J; Becker S; Jardin F; Mounier N; Salles G; Lancet Haematol; 2018 Sep; 5(9):e403-e410. PubMed ID: 30172345 [TBL] [Abstract][Full Text] [Related]
35. Pretreatment SUV Strati P; Ahmed MA; Nastoupil LJ; Feng L; Hagemeister FB; Fayad LE; Rodriguez MA; Samaniego F; Wang M; Westin JR; Lee HJ; Iyer SP; Parmar S; Ahmed S; Nair R; Steiner RE; Noorani M; Flowers CR; Davis RE; Fowler NH; Neelapu SS Leuk Lymphoma; 2020 Jun; 61(6):1380-1387. PubMed ID: 31971032 [TBL] [Abstract][Full Text] [Related]
36. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Keating GM Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951 [TBL] [Abstract][Full Text] [Related]
37. Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup. Jiang S; Qin Y; Jiang H; Liu B; Shi J; Meng F; Liu P; Yang J; Yang S; He X; Zhou S; Gui L; Liu H; Lin J; Han-Zhang H; Shi Y Int J Cancer; 2020 Nov; 147(9):2611-2620. PubMed ID: 32399964 [TBL] [Abstract][Full Text] [Related]